{"SPADE_N_14381": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_N_14381", "Peptide Name": "KHS-Cnd F1W (Cnd-m3, Chionodracine analog, synthetic AMPs, Lys-rich, UCLL1)", "Source": "amino acid substitution, animal-derived, natural derivative", "Family": "Not found", "Gene": "Not found", "Sequence": "WFGKLYRGITKVVKKVKGLLKG", "Sequence Length": 22, "UniProt Entry": "Ref", "Protein Existence": "Not found", "Biological Activity": ["Anti-Gram+", "Anti-Gram-"], "Target Organism": "Not found", "Hemolytic Activity": "Not found", "Cytotoxicity": "Not found", "Binding Target": "Not found", "Linear/Cyclic": "Not found", "N-terminal Modification": "Not found", "C-terminal Modification": "Not found", "Stereochemistry": "Not found", "Structure Description": "Not found", "Formula": "Not found", "Mass": 2519.12, "PI": 10.75, "Hydrophobicity": -0.05, "Half Life": "Not found", "Function": "Not found", "Literature": [{"Author": "Olivieri C, Bugli F, Menchinelli G, Veglia G, Buonocore F, Scapigliati G, Stocchi V, Ceccacci F, Papi M, Sanguinetti M, Porcelli F. 2018", "Reference": "RSC Adv. 2018 Dec 12;8(72):41331-41346. doi: 10.1039/c8ra08065h.PubMed", "Title": "Design and characterization of chionodracine-derived antimicrobial peptides with enhanced activity against drug-resistant human pathogens."}], "Frequent Amino Acids": "KGL", "Absent Amino Acids": "ACDEHMNOPQSU", "Basic Residues": 7, "Acidic Residues": 0, "Hydrophobic Residues": 10, "Polar Residues": 12, "Positive Residues": 7, "Negative Residues": 0, "Net Charge": 7, "Comments": "Sequence analysis: APD analysis reveals that this sequence is similar (72.73%) toChionodracineK: 27%, G: 18%, V=L: 14%.Activity: active against K. pneumoniae KPC (MIC 0.3-1.2 uM), ESBL E. coli (MIC 0.6-2.5 uM), XDR A. baumannii (MIC 0.6-1.2 uM), MDR P. aeruginosa (MIC 1.2-5.0 uM), S. aureus MRSA (MIC 5.0-19.9 uM), S. epidermidis (MIC 0.6-2.5 uM), and E. faecalis anti-VRE (MIC 0.6-2.5 uM).  In total, 70 clinical strains were tested and the results are expressed as a range. Also showed activity against biofilms:bacteria:P. aeruginosa (Artini et al., 2022). It appeared to have effects on protease levels of certain P. aeruginosa strains.Structure:  random coil in PBS buffer and helical in POPC (1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) LUVs ((Large Unilamellar Vesicles).In vitro toxicity: human RBC: ~25% hemolysis at 50 uM.", "Similar Sequences": [{"SPADE_ID": "SPADE_UN_22445", "Similarity": 1.0, "Sequence": "WFGKLYRGITKVVKKVKGLLKG"}, {"SPADE_ID": "SPADE_UN_15814", "Similarity": 0.9545454545454546, "Sequence": "WFGKLYRGKTKVVKKVKGLLKG"}, {"SPADE_ID": "SPADE_N_14380", "Similarity": 0.9090909090909091, "Sequence": "WFGKLYRGITSVVKKVKGLLSG"}]}}}